Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On August 18, 2021, Salarius Pharmaceuticals, Inc. (the "Company") was notified
(the "Notice") by Nasdaq Stock Market, LLC ("Nasdaq") that on August 17, 2021
the average closing price of the Company's common stock (the "Common Stock")
over the prior 30 consecutive trading days had fallen below $1.00 per share,
which is the minimum average closing price required to maintain listing on
Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Requirement").
The Notice has no immediate effect on the listing or trading of the Company's
common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company
has 180 calendar days to regain compliance with the Minimum Bid Requirement. To
regain compliance, the closing bid price of the Company's common stock must be
at least $1.00 per share for a minimum of ten consecutive business days before
February 14, 2022.
If the Company does not achieve compliance with the Minimum Bid Requirement
during the initial 180 calendar day period, the Company may be eligible for an
additional 180 calendar day compliance period. To qualify, the Company would be
required to meet the continued listing requirement for market value of publicly
held shares and all other Nasdaq initial listing standards, with the exception
of the bid price requirement, and would need to provide written notice of its
intention to cure the deficiency during the second compliance period. However,
if it appears to Nasdaq staff that the Company will not be able to cure the
deficiency, or if the Company does not meet the other listing standards, Nasdaq
could provide notice that the Company's common stock will become subject to
delisting. In the event the Company receives notice that its common stock is
being delisted, Nasdaq rules permit the Company to appeal any delisting
determination by the Nasdaq staff to a Hearings Panel.
There can be no assurance that the Company will be able to regain compliance
with the Minimum Bid Requirement or maintain compliance with the other listing
requirements.
The Company intends to actively monitor the closing bid price of its common
stock and will evaluate available options to regain compliance with the Minimum
Bid Requirement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses